Contineum Therapeutics, Inc. (CTNM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CTNM currently has 32.7M outstanding shares. with significant dilution risk as 107M authorized shares could dilute existing holders by 327.5%. The company has significantly diluted shareholders by 64.51% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 32.7M shares outstanding |
33M | 110M |
| Oct 30, 2025 |
10-Q filing | 22.8M shares outstanding |
23M | 110M |
| Aug 05, 2025 |
10-Q filing | 19.2M shares outstanding |
19M | 110M |
| May 14, 2025 |
S-3 filing: The company is filing an S-3 to offer and sell up to $300 million in the aggregate of Class A common stock, preferred stock, and debt securities from time to time. |
19M | 110M |
| May 14, 2025 |
10-Q filing | 19.1M shares outstanding |
19M | 110M |
| May 14, 2025 |
8-K filing: The Company filed a shelf registration statement for the sale of up to $300 million in securities and entered into a sales agreement with Leerink Partners LLC for the offer and sale of up to $75 million in shares of its Class A common stock through an at-the-market offering. |
19M | 110M |
| Mar 06, 2025 |
10-K filing | 19.4M shares outstanding |
19M | 9.3M |
| Nov 06, 2024 |
10-Q filing | 19.0M shares outstanding |
19M | 9.3M |
| Aug 14, 2024 |
10-Q filing | 19.0M shares outstanding |
19M | 9.3M |
| May 16, 2024 |
10-Q filing | 2.4M shares outstanding |
2.4M | 9.3M |
| Apr 01, 2024 |
S-1/A filing: This S-1/A filing relates to an offering of Class A common stock by Contineum Therapeutics, Inc., with an option for the underwriters to purchase additional shares. |
25M | 9.3M |
| Mar 15, 2024 |
S-1 filing: This S-1 filing by Contineum Therapeutics, Inc. relates to an initial public offering of Class A common stock, with an option for underwriters to purchase additional shares, and details the company's plans for use of proceeds, capital structure, and financial data. |
100M | 0 |